Clinical mastitis in cows treated with sometribove (recombinant bovine somatotropin) and its relationship to milk yield

How to use recombinant bovine somatotropin in crossbred Holstein × Gyr (3/4 and 7/8) cows?

The aim of this study was to evaluate the effects of dose, start time, and application interval of recombinant bovine somatotropin (rbST) on performance, health, and reproduction parameters of crossbred Holstein × Gyr dairy cows (3/4 and 7/8). A 2 × 2 × 2 factorial study was designed to test the effects of application dose (250 mg rbST or 500 mg rbST), start of application (40 or 63 days in milk (DIM)), and application interval (12 or 14 days); 180 crossbred Holstein × Gyr cows were enrolled. Treatments with 500 mg rbST resulted in increased milk production, 3.5% fat-corrected milk (FCM), and energy-corrected milk (ECM). In the factorial design analysis, greater FCM, ECM, and milk solid production (kg/day) were observed when 500 mg rbST was started at 63 DIM, while 250 mg rbST resulted in greater milk production (kg/day), FCM, ECM, and milk solids (kg/day) when administered at 12-day intervals. Administration of 500 mg rbST resulted in an increase of days open and number of services per pregnancy (P = 0.01). Holstein × Gyr cows (3/4 and 7/8) presented a superior productive response to rbST when treated with 500 mg starting at 63 DIM and at 14-day intervals.

The Impacts of Climate Change Mitigation Strategies on Animal Welfare

The objective of this review is to point out that the global dialog on reducing greenhouse gas emissions in animal agriculture has, thus far, not adequately considered animal welfare in proposed climate change mitigation strategies. Many suggested approaches for reducing emissions, most of which could generally be described as calls for the intensification of production, can have substantial effects on the animals. Given the growing world-wide awareness and concern for animal welfare, many of these approaches are not socially sustainable. This review identifies the main emission abatement strategies in the climate change literature that would negatively affect animal welfare and details the associated problems. Alternative strategies are also identified as possible solutions for animal welfare and climate change, and it is suggested that more attention be focused on these types of options when allocating resources, researching mitigation strategies, and making policy decisions on reducing emissions from animal agriculture.

Meta-analysis of the effects of sometribove zinc suspension on the production and health of lactating dairy cows

OBJECTIVE

To provide an updated evaluation of the efficacy and safety of sometribove zinc suspension (rbST-Zn), a form of recombinant bovine somatotropin, in lactating dairy cows.

DESIGN

Meta-analysis.

SAMPLE

26 studies published in peer-reviewed journals or reviewed by a regulatory agency.

PROCEDURES

To be included, a study had to involve the use of the rbST-Zn formulation available to US producers in accordance with the label instructions for treatment initiation (57 to 70 days postpartum), dose (500 mg, q 14 d), and route (SC).

RESULTS

For cows treated with rbST-Zn, mean milk, 3.5% fat-corrected milk, fat, and protein yields were increased by 4.00, 4.04, 0.144, and 0.137 kg/d (8.8, 8.89, 0.32, and 0.30 lb/d), respectively; however, the concentration of milk components did not change. Pregnancy proportion for the first 2 breeding cycles was increased by 5.4%, and pregnancy proportion for the duration of the trial was reduced by 5.5% for rbST-Zn-treated cows, compared with proportions for untreated cows. Mean body condition score (1 to 5 scale) was reduced by 0.06 points during the period of rbST-Zn use for treated cows. Administration of rbST-Zn had no effect on milk somatic cell count, the number of days to pregnancy, or inseminations per pregnancy; rates of fetal loss, twins, cystic ovaries, clinical lameness, lameness lesions, or traumatic lesions of the integumentary system; and odds of clinical mastitis or culling.

CONCLUSIONS AND CLINICAL RELEVANCE

Results indicated that rbST-Zn administration to dairy cows effectively increases milk production with no adverse effects on cow health and well-being.

Supplementing Holstein cows with low doses of bovine somatotropin prepartum and postpartum reduces calving-related diseases

The objective of this study was to evaluate whether supplementing Holstein cows with bovine somatotropin (bST; 142.8 mg/14 d), beginning at 21 d (+/-3 d) before expected calving and continuing through 42 d in milk (+/-3 d), affected the incidence rates of retained fetal membranes (RFM), metritis (MET), clinical mastitis (MAS), digestive problems (DIG), ketosis (KET), milk fever (MF), displaced abomasum (DA, left or right), lameness (LAM), or number of sick cows during the first 60 d in milk. Data for multiparous Holstein cows from 3 separate trials were merged for analyses (n = 437). Cows in the bST-supplemented group (n = 162) received biweekly subcutaneous injections of Posilac, whereas control cows (n = 166) and a group of cohorts (n = 109) were not supplemented. Incidences of disease were collected from the herd health records. Across all treatment groups, the incidence rates (number of diseased cows divided by the total number of cows) for RFM, MET, MAS, DIG, KET, MF, DA, and LAM were 8.47, 18.31, 16.02, 4.35, 4.35, 3.66, 3.20, and 3.66%, respectively. The incidence rates of RFM, MET, MAS, DIG, KET, MF, DA, and LAM for cows in the bST-supplemented, control, and cohort groups were 6.79, 7.83, and 11.93%; 16.05, 7.47, and 22.94%; 10.49, 18.07, and 21.10%; 1.23, 5.42, and 7.34%; 1.23, 6.02, and 6.42%; 2.47, 4.22, and 4.59%; 2.47, 3.61, and 3.67%; and 3.70, 3.61, and 3.67%, respectively. The percentages of sick cows (number of cows having one or more cases of disease divided by the total number of cows) in the bST-supplemented, control, and cohort groups were 33.95, 43.37, and 49.54%, respectively. Significant chi-squared values were detected between the bST-supplemented and control groups for MAS, DIG, and KET, with a greater number of healthy cows in the bST-supplemented group. No differences in incidences of diseases or sick cows were detected between the control and cohort groups. Results indicated that a low dose of bST supplemented to Holstein cows for 3 wk prepartum through 60 d in milk reduced the incidences of some calving-related diseases compared with nonsupplemented controls or cohorts. Importantly, no negative effects of bST supplementation on postpartum calving diseases were detected compared with nonsupplemented cows.

An approach to identify dairy cows being responsive to recombinant bovine somatotropin

Forty-eight primiparous and pregnant Holstein cows at 202 (+/-59) days in milk and average daily milk production (DMP) of 22 (+/-5.3) kg at the beginning of the trial were used to study the possibility of identifying animals that are more responsive to recombinant bovine somatotropin (rbST). Animals were housed in free-stall barns, milked three times a day and fed a total mixed ration. Animals were injected with one dose (500 mg each) of rbST every 21 days during a 105-day total period (five doses in all). Daily milk production was recorded to measure average apparent response (AAR) and peak of apparent response (PAR). Average apparent response was defined as the average increase in milk production, expressed as kilogram per cow per day, for days 0-18 after dosing, as compared to the average production calculated for days -1, -2, -3, 19, 20 and 21 after dosing. Peak of apparent response was calculated as the increase in milk production for each day from 0 to 18 days after dosing as compared to the average production for days -1, -2 and -3. There was a positive linear correlation (r = 0.608; p = 0.0001) between AAR for the first 21 days and AAR for the total 105-day period (AATR). A correlation coefficient was calculated between each individual PAR value and AATR. The highest correlation coefficient (r = 0.511; p = 0.0002) was observed for days 8, 9 and 10, and therefore these days were considered the best estimates for calculating AAR when DMP records are not available. Also, high somatic cells count had a negative impact on milk yield response to treatment (p = 0.0162).

Effect of Increased Milking Frequency in Early Lactation With or Without Recombinant Bovine Somatotropin

Multiparous Holstein cows (n = 300) were assigned to 1 of 2 milking frequency treatments at parturition. Cows were either milked 6 times (6x) or 3 times (3x) daily to determine effects on early lactation milk yields and subsequent lactation persistency with or without use of recombinant bST (rbST). Treatments included a control group milked 3x and 3 groups milked 6x for either the first 7, 14, or 21 days in milk (DIM). Those 4 groups of cows all received rbST starting at 63 DIM. The fifth treatment group was also milked 6x for the first 21 DIM but those cows received no rbST during the entire lactation. All cows returned to 3x milking after their respective treatment periods ended. Cows milked 3x tended to produce more milk (43.2 vs. 41.5 and 41.0 +/- 1.1 kg/d) during the first 9 wk of lactation compared with cows milked 6x for 7 or 21 DIM, respectively. Group milk yields after wk 9 averaged 38.3 +/- 0.7 kg/d and did not differ among various groups assigned to an increased milking frequency in early lactation. Percentages of milk fat (3.8 +/- 0.12%) and protein (2.9 +/- 0.06%) did not differ among treatments during the first 9 wk after calving. Early lactation milk yield (41.9 +/- 1.2 kg/d) did not differ between the 2 groups of cows milked 6x for 21 DIM. However, cows subsequently administered rbST (at 63 DIM) produced more milk (38.8 vs. 34.2 +/- 0.9 kg/d) from wk 10 to 44. The number of cows sent to the hospital during the 305-d trial for mastitis (97), digestive disorders (14), respiratory issues (9), lameness (22), or retained placenta (16), were not affected by treatments (chi(2) = 0.49). Under the conditions of this commercial dairy herd in Arizona, increasing milking frequency to 6 times daily for 7 to 21 d at the start of lactation conditions did not increase milk yield nor improve lactation persistency.

Low Doses of Bovine Somatotropin During the Transition Period and Early Lactation Improves Milk Yield, Efficiency of Production, and Other Physiological Responses of Holstein Cows

The objectives of this experiment were to determine whether low doses of bovine somatotropin (bST) during the transition period and early lactation period improved dry matter intake (DMI), body weight (BW), or body condition score (BCS); provoked positive changes in concentrations of somatotropin, insulin, insulin-like growth factor-I (IGF-I), glucose, nonesterified fatty acids, and Ca; or improved milk yield (MY) response without obvious adverse effects on health status. Eighty-four multiparous Holstein cows completed treatments arranged in a 2 x 3 x 2 factorial design that included prepartum and postpartum bST, dry period (30 d dry, 30 d dry + estradiol cypionate, and 60 d dry), and prepartum anionic or cationic diets. Biweekly injections of bST began at 21 +/- 3 d before expected calving date through 42 +/- 2 d postpartum (control = 0 vs. bST = 10.2 mg of bST/d; POSILAC). At 56 +/- 2 d in milk, all cows were injected with a full dose of bST (500 mg of bST/14 d; POSILAC). During the prepartum period and during the first 28 d postpartum, no differences in mean BW, BCS, or DMI were detected between the bST treatment group and the control group. During the first 10 wk of lactation, cows in the bST treatment group had greater mean MY and 3.5% fat-corrected milk yield and lower SCC than did cows in the control group. When cows received a full dose of bST, an increase in milk production through wk 21 was maintained better by cows in the bST group. Mean concentrations of somatotropin, IGF-I, and insulin differed during the overall prepartum period (d -21 to -1). During the postpartum period (d 1 to 28), cows in the bST group had greater mean concentrations of somatotropin and IGF-I in plasma. Concentrations of Ca around calving did not differ because of bST treatment. Results suggest that changes in concentrations of blood measures provoked by injections of bST during the transition period and early lactation period resulted in improved metabolic status and production of the cows without apparent positive or negative effects on calving or health.

Effects of sustained release bovine somatotropin (sometribove) on animal health in commercial dairy herds

The health of dairy cows given bovine somatotropin (bST) for one lactation was evaluated in 28 commercial herds located in four regions of the United States. At least six herds were in a region and at least one herd/region contained fewer than 60 cows. Cows (n = 1213) were assigned randomly to control or bST groups and were treated beginning in wk 9 to 10 of lactation and every 14 d until dry-off or d 400 of lactation. Management was according to site practices. Cows were observed for health-related signs by farm personnel daily and by the herd veterinarian biweekly. Average 305-d test-day milk yields were 932 kg greater for bST-treated cows. Pregnancy rates, days open, twinning, cystic ovaries, or abortions were unaffected by treatments. Supplementation of cows with bST had no effect on total mastitis cases, total days of mastitis, duration of mastitis, or the odds ratio of a cow to develop mastitis. Cows supplemented with bST used more medications for health events other than mastitis. This usage was associated primarily with treatments for disorders of the foot and hock. Supplemented cows had a slight increase in foot disorders. There was no effect of supplementation with bST on culling from the herd or removal from study. Overall, the results confirm that label directions for bST are adequate for safe use under field conditions. All clinical signs observed in this study occur normally in dairy herds and were managed in cows supplemented with bST.

The role of food ethics in food policy

Certain developments in the agricultural and food sciences have far-reaching implications for society and the environment, which suggest the need to examine their ethical acceptability as a standard component of technology assessment. Such considerations have led to the emergence of a new academic discipline, food ethics. The present paper describes how ethical theory may be applied to the analysis of the impacts of prospective food biotechnologies to assess potential effects on four 'interest groups', i.e. consumers, producers, treated organisms and the biota (fauna and flora). The principles which structure the framework used, i.e. the ethical matrix, are adapted to the field of agriculture and food from those applied in medical ethics. Use of the ethical matrix is illustrated by applying it to the specific case of bovine somatotrophin, the genetically-engineered protein hormone which is injected into lactating cattle to increase their milk yields. Ethical analysis is seen to depend on a number of critical requirements, i.e. scientific data, non-scientific evidence and predictions, suitably-qualified assessors ('competent moral judges'), the 'world-views' of the assessors and application of the precautionary principle to cope with 'uncertainty'.

Production responses to bovine somatotropin in northeast dairy herds

The commercial response to bovine somatotropin was examined in northeast dairy herds from 1990 to 1998 (4-yr preapproval and 4-yr postapproval). With DHI records and Monsanto customer files, a control group (never purchased Posilac) and a bovine somatotropin (bST) group (used on at least 50% of cows) were identified. A total of 340 herds were involved and, over the 8-yr period, there were over 80,000 cows, 200,000 lactations, and 2 million test days. Herd management comparisons demonstrated the response to bST was relatively constant each year of the postapproval period. Assuming 100% of cows were supplemented, response to bST over a 305-d lactation equaled 894 kg of milk, 27 kg of milk fat, and 31 kg of milk protein. Comparisons of lactation curves were used to identify where the bST response occurred in the lactation cycle. Analysis demonstrated the responses in milk, milk fat, and protein yield were minimal in the early phase of lactation, and then gradually increased until reaching a plateau over the last half of the lactation cycle. Persistency of lactation was also improved by bST, indicating the opportunity exists to extend lactation with combined use of bST and altered reproductive management. Average age and days in milk did not differ between control and bST herds. Thus, stayability and herd-life of animals were not altered by bST treatment. Somatic cell count (SCC) linear scores were minimally affected in herds utilizing bST and the pattern of SCC over the lactation cycle was unaffected. Overall bST improved lactation yield and persistency consistently over the 4-yr postapproval period with no effects on cow stayability and herd-life.

Effects of monensin on the reproduction, health, and milk production of dairy cows

A randomized clinical trial including 1109 cows from 12 Australian dairy herds was used to evaluate the effects of monensin on the health (n = > 686 cows), production (n = 915 cows), and reproduction (n = > 908 cows) of dairy cows. Cows were allocated to a treatment group receiving a slow-release intraruminal bolus containing 32 g of sodium monensin that was administered 40 d before and 50 d following the anticipated calving date or to a control group. Treatment did not significantly alter any reproductive outcome; 54.5% of cows treated with monensin and 58.2% of control cows were pregnant at first service, and days to conception were lower for cows treated with monensin. The hazard rate (0.95) was not significant for these cows. The percentage of cows pregnant was 83.8 for control cows, and days to first estrus (hazard rate = 1.04) and first service (hazard rate = 1.04) were not significantly higher for treated cows. Treatment with monensin did not significantly alter the risk of any disease. The incidence of retained fetal membranes, pyometra, lameness, abortion, and infectious diseases was not significantly lower for cows in the treatment group, and the incidence of mastitis was not significantly higher for cows in the treatment group. Monensin significantly increased milk production by 0.75 L/d per cow and tended to increase milk fat and protein yields but had no significant effect on milk fat or milk protein percentages. Changes in the production of milk and milk constituents were consistent throughout lactation.

Response of Brazilian crossbred cows to varying doses of bovine somatotropin

The effect of n-methionyl bovine somatotropin (bST) on milk yield was evaluated in crossbred cows (40 1/2 Bos indicus x 1/2 Bos taurus and 18 1/4 B. indicus x 3/4 B. taurus) in Brazil. Cows were randomly assigned to treatments within stage of lactation [stage 1 = 56 to 100 d in milk (DIM); stage 2 = 101 to 199 DIM] and breed groups (1/2 vs. 1/4 B. indicus blood). Treatments were 250 or 500 mg of bST administered every 14 d. Cows in the control group did not receive bST or a placebo. Treated cows received bST injected subcutaneously in the postscapular region, alternating between the left and right sides. The 26-wk experiment consisted of 2 wk of pretreatment and 24 wk of treatment. Cows were housed in an open lot with regulated access to pasture. Cows were milked twice daily and scored for body condition at 2-wk intervals. Compared with controls, milk yield increased equally (22%) for cows receiving 250 or 500 mg of bST. Milk yield response to bST was higher and persisted longer during stage 1 of lactation than during stage 2 of lactation. No difference in response to bST was noted between cows with 1/2 or 1/4 B. indicus blood. Cows treated with 500 mg of bST tended to have more mastitis, but no other adverse health effects were observed. The potential use of 250-mg doses of bST at 14-d intervals in crossbred cattle in Brazil and other subtropical regions throughout the world is suggested, particularly before about 220 DIM.

Recombinant bovine somatotropin and clinical mastitis: incidence, discarded milk following therapy, and culling

Holstein cows (n = 555) from four Michigan dairy farms were randomly assigned to receive bovine somatotropin (bST) or to serve as untreated controls. Bovine somatotropin (500 mg) was administered every 14 d beginning at 63 to 69 d of lactation and continuing until approximately 21 d prior to dry-off or until the cow was removed from the herd. Trial objectives were to determine the effect of bST on the incidence of clinical mastitis, number of days that milk was discarded because of therapy for clinical mastitis, and culling for mastitis. A total of 127 (22.9%) cases of clinical mastitis occurred during lactation. In the pretrial period (before 63 to 69 d of lactation), 42 (33.1%) cases occurred, and 85 (66.9%) cases occurred during the trial. Of the 42 pretrial cases, 57.1% occurred in control cows, and 42.9% occurred in treated cows. Of the 85 trial cases 47.1% occurred in control cows, and 52.9% occurred in treated cows. Using logistic regression, the odds ratio for the occurrence of clinical mastitis in treated cows was 1.06 (95% confidence interval = 0.62 to 1.81). The number of days that milk was discarded following therapy for clinical mastitis and the culling rate for mastitis did not differ between study groups.

Effect of calcium soaps of fatty acids and administration of somatotropin in early lactation on productive and reproductive performance of high producing dairy cows

This study examined the mechanisms by which calcium soaps of fatty acids and bovine somatotropin (bST) affect production and reproduction of high producing cows. Calcium soaps of fatty acids were fed at 2.2% dry matter, and 500 mg of Zn-sometribove (Monsanto Inc., St Louis, MO) were injected subcutaneously every 14 d from 10 to 150 d in milk (DIM). Production of fat-corrected milk was increased by 3.5 kg/d when calcium soaps of fatty acids were fed, by 6.1 kg/d when bST was administered, and by 7.4 kg/d when calcium soaps of fatty acids were fed and bST was administered. Body weight was similar for cows on all treatments until 85 DIM after which cows that were treated with bST had lower body weights. Body condition scores decreased more for cows treated with bST and began increasing later and more slowly. Treatment with bST resulted in more cows that experienced first ovulation after 30 DIM, and more cows on the control treatment exhibited first estrus before 35 DIM. Days open were greater when bST was administered. After the first artificial insemination, conception rates were similar for cows on the control treatment and for cows fed calcium soaps of fatty acids; conception rates after the first artificial insemination were low for all cows treated with bST. Pregnancy rates at 120 and 150 DIM were decreased by bST. Number of DIM to first ovulation, number of DIM to first estrus, and days open were negatively correlated with glucose and cholesterol concentrations in plasma. Production of fat-corrected milk was correlated with days open and with concentrations of triglycerides in plasma, nonesterified fatty acids, and cholesterol. Increased production had different effects on reproduction when induced by calcium soaps of fatty acids or bST treatment. Some of the adverse effects of bST treatments were alleviated by calcium soaps of fatty acids.

Predictive model of mastitis occurrence in the dairy cow

Mastitis occurrence within a lactation and times of mastitis onset were studied for about 1000 cows. The number of mastitis cases within a lactation was modeled through overdispersed Poisson regression with individual and herd covariants. The results emphasized the role of the herd variable. Increased production potential increased the number of cases per lactation at a rate of 1.4/10 kg. Calving month also played an important role. The incidence of mastitis was greater when calving took place in early autumn or winter, which led to an expanded housing period. The interval from calving to the first case of mastitis and the intervals between successive cases were modeled for cases occurring during lactation through random selections from fitted gamma distributions, these distributions being truncated to consider the lactation length. The results of both steps can be used to simulate mastitis occurrence in different conditions.

Plagiarism or protecting public health?

Is milk produced using recombinant bovine growth hormone hazardous to animal health? Despite wide publicity, the controversy remains unresolved. Rapid publication of all available data is essential if progress is to be made.